Life Sciences

We are unquestionably one of the premier law firms representing companies in the pharmaceutical sector. Our practice has been known as a leading player in the IP arena for decades and is “hands down the best generic-side ANDA/Hatch-Waxman patent litigation group” (U.S. News―Best Lawyers® “Best Law Firms”). Since 2020, we have appeared in 60 pharmaceutical patent cases and, over the years, we have obtained wins in matters involving blockbuster drugs such as Zubsolv®, Prozac®, Yasmin®, Baraclude®, Razadyne ER/Razadyne IR®, Temodar®, Amrix®, Amprya®, Sensipar®, and Testim®, among others.

In addition to fiercely protecting our clients’ intellectual property and freedom to innovate, we are often tasked with defending clients’ products and reputations. Leading pharmaceutical companies repeatedly turn to us to serve in key roles—lead trial counsel, multidistrict litigation counsel, state-wide coordinating counsel, appellate counsel—to resolve their most critical product liability issues. Our lawyers have been involved in some of the most-watched, “bet-the-company” product liability and mass tort cases in recent history, such as serving as defense counsel for Pfizer Inc. in the wave of product liability cases regarding its two prescription non-steroidal anti-inflammatory medications, Celebrex® and Bextra®; trial counsel for Wyeth Pharmaceuticals in the Fen-Phen product liability litigation; co-lead counsel for Otsuka in the In re: Abilify (Aripiprazole) Products Liability Litigation MDL, various state-court actions brought by more than 4,000 plaintiffs, and the Abilify® and Rexulti® failure-to-warn and design defect cases; and national counsel for Hikma Pharmaceuticals in the national opiate litigation.

Furthermore, our attorneys have extensive experience in matters involving state and federal government law enforcement and investigations. With former U.S. Department of Justice attorneys and in-house attorneys embedded in our Healthcare and Life Sciences Industry Group, we can leverage our practitioners’ experience to provide efficient and creative representation of our clients in a broad array of important False Claims Act (FCA) matters, including those covering such issues as drug price reporting of Average Wholesale Price and Medicaid Drug Rebate Best Price and sales to government purchasers on the Federal Supply Schedule. We also routinely guide clients through many of the industry’s most-litigated FCA issues in the current environment. These include dealing directly with regulators on litigated, non-intervened FCA qui tam matters involving complex Stark and anti-kickback issues, violation of drug-pricing allegations, and others.

Our life sciences attorneys have deep experience with product development and commercialization across the leading sectors of the life sciences industry, including biotechnology. Our team recognizes that biotechnology is a highly diversified, complex, and regulated industry, and we partner with our clients to help them navigate the research, financing, and commercialization stages of product development. Our team is fully integrated with all the firm’s substantive practices, and we draw upon decades of experience to help bring important biotech products to market successfully.

Since the Biologics Price Competition and Innovation Act (BPCIA), or Biosimilars Act, was enacted in March 2010, our attorneys have played a pivotal role in some of the first cases in district courts and in proceedings before the U.S. Patent and Trademark Office. We are one of the few firms with hands-on experience litigating these cases and regularly present on BPCIA issues at conferences and other industry events. Currently, we advise a number of clients on potential biosimilar applications under the BPCIA, analyzing and preparing patent opinions regarding validity, infringement, freedom to operate, and related issues, including determining how best to proceed under the particular client’s circumstances.